<DOC>
	<DOCNO>NCT02064634</DOCNO>
	<brief_summary>This study investigate gastrointestinal toxicity affect discontinuation medication give patient osteoarthritis routine clinical practice .</brief_summary>
	<brief_title>A Prospective Observational Study Discontinuation Medication Shinbaro Capsule</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Minimum 20 yearold patient diagnose osteoarthritis Within 2 week prior participation , take antiinflammatory analgesic drug Shinbaro Capsule , Celecoxib Capsule NSAIDs ( nonsteroidal antiinflammatory drug ) Written consent form voluntarity Diagnosed disease may affect measurement efficacy clinically Diagnosed clinically significant phycological disorder , take medication Participated clinical trial within 4 week Pregnant lactate woman History malignant disease within previous 5 year Patients seem participate study investigator 's discretion</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Shinbaro Capsule</keyword>
	<keyword>Celecoxib</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>GCSB-5</keyword>
	<keyword>Discontinuation rate</keyword>
	<keyword>Gastrointestinal adverse event</keyword>
	<keyword>NSAIDs</keyword>
	<keyword>OASIS</keyword>
</DOC>